Eterna Therapeutics Inc. announced the appointment of Peter Cicala, JD, to its Board of Directors. Mr. Cicala's professional expertise focuses on all aspects of pharmaceutical and biotechnology intellectual property and strategic management of proprietary technology and products. His most recent experience involves advising start-up and venture-backed biotechnology companies through all aspects of drug development and the protection of proprietary technologies, including long-range strategic planning and commercialization of therapeutics.

Mr. Cicala has extensive experience in patent litigation, prosecution, product lifecycle management, R&D collaborations, M&A transactions, and joint ventures in the pharma/biotech industry, including small molecule, antibody and CAR-T products. Mr. Cicala has substantial experience with patent and regulatory litigation in most major pharmaceutical markets. Additionally, Mr. Cicala has over ten years of experience as a medicinal chemist and has worked on drug development programs for several major pharmaceutical companies and universities.

Mr. Cicala graduated from Seton Hall University School of Law and has a Bachelor of Science in Chemistry from Fairleigh Dickinson University.